Form 4: Apellis Pharmaceuticals Executive Karen Lewis Reports Stock Sale to Cover Tax Withholding

Karen Lewis, Chief People Officer of Apellis Pharmaceuticals, sold 1,599 shares of common stock on January 13, 2025, to cover tax obligations related to released Restricted Stock Units.

Summary

• Karen Lewis, Chief People Officer of Apellis Pharmaceuticals, reported a transaction involving the company's common stock.
• On January 13, 2025, Lewis sold 1,599 shares at a price of $28.7021 per share.
• This sale was to cover tax withholding on Restricted Stock Units released on January 10, 2025.
• Following the transaction, Lewis beneficially owns 45,099 shares of Apellis Pharmaceuticals.
• This total includes 116 shares from an April 30, 2024, Employee Stock Purchase Plan (ESPP) purchase and 195 shares from an October 31, 2024, ESPP purchase.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing detailing a stock sale for tax purposes. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This particular transaction appears to be routine, covering tax obligations related to equity compensation.

Comparison to Industry Standards

• Insider sales to cover tax obligations are a common occurrence across publicly traded companies, especially after the vesting of restricted stock units or the exercise of stock options.
• The sale of 1,599 shares is relatively small compared to the total holdings of 45,099 shares, suggesting it's a routine transaction rather than a significant divestment.
• Companies like Regeneron, Alnylam, and Biogen also see similar Form 4 filings from their executives regularly.

Key Dates